FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease

Why it matters locally: Sickle cell disease is prevalent in Alabama, making this FDA approval significant for children and families across the state who may benefit from this new gene therapy option. Healthcare providers and facilities, including those in Jefferson County, will be evaluating how to integrate this treatment into care.

The U.S. Food and Drug Administration (FDA) today announced a supplemental approval for Casgevy (exagamglogene autotemcel). This expanded approval permits the use of the gene therapy for patients aged two years and older. The therapy is indicated for individuals diagnosed with sickle cell disease (SCD) who experience recurrent vaso-occlusive crises (VOCs). Additionally, the approval covers patients with transfusion-dependent beta thalassemia (TDT).